Compounded GLP-1 Telehealth Pricing Floor Update — Ozari's $86/Month Semaglutide Anchors the Low End as 503B Bulks-List Comments Close June 29
Tuesday's Ozari Health launch at $86/month for compounded semaglutide and $120/month for compounded tirzepatide places the platform at the low end of the compounded GLP-1 telehealth pricing band. Comparable platforms in the same market: Sesame ~$99/month, Henry Meds $129-249/month, Wisp ~$199/month, Mochi Health $129/month introductory, MD Lifestyle $99-249/month. The pricing-floor compression is colliding with the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — comments close June 29, with the final determination expected late Q3 2026. If the FDA's 503B proposal stands, large-scale 503B compounding ends and platforms either shift to 503A pharmacies (lower volume, higher unit cost) or wind down. The current cohort of telehealth launches at $86-129/month likely represents the cheapest US compounded GLP-1 will be before the regulatory regime tightens. Branded Wegovy and Foundayo's $25-149/month commercial-insurance copays remain the lower-cost path for insured patients; the cash-pay compounded market is what these telehealth launches are competing for.